NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models

被引：0
|
作者：
Carragher, Neil O.
Dash, Sweta
Nyswaner, Katherine
Harvey, Mungo J. B.
King, Ben
Woods, Allison
Unciti-Broceta, Asier
Poradosu, Enrique
Brognard, John
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B162
引用
收藏
页数：2
相关论文
共 11 条
  • [1] Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models
    Dash, Sweta
    Nyswaner, Katherine
    Harvey, Mungo J. B.
    King, Ben
    Woods, Allison
    Carragher, Neil O.
    Unciti, Asier
    Poradosu, Enrique
    Brognard, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] NXP900, a novel YES1/SRC kinase inhibitor in phase 1, demonstrates potent inhibition of proliferation in cell lines resistant to ALK and EGFR inhibitors
    Carragher, Neil O.
    Poradosu, Enrique
    King, Ben
    Munro, Alison F.
    Dawson, John C.
    Unciti-Broceta, Asier
    CANCER RESEARCH, 2024, 84 (06)
  • [3] NXP900, a novel YES1/SRC Kinase Inhibitor in Phase 1 Dose Escalation, Demonstrates Potent Synergy with ALK Inhibitors in ALK Resistant Cell Lines
    Unciti-Broceta, A.
    Poradosu, E.
    Carragher, N. O.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S92 - S92
  • [4] NXP800, a novel, small molecule GCN2 kinase activator, demonstrates potent single-agent activity in ARID1A and ARID1B-deficient endometrial cancer xenograft models
    Eskander, Ramez N.
    Monk, Bradley J.
    Slomovitz, Brian M.
    Poradosu, Enrique
    Woods, Allison
    Shemesh, Shay
    Clarke, Paul
    Poele, Robert Te
    Powers, Marissa
    Workman, Paul
    Westin, Shannon N.
    CLINICAL CANCER RESEARCH, 2024, 30 (05)
  • [5] Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models
    Wu, Wenjuan
    King, Constance
    Donoho, Gregory
    Iversen, Philip
    Capen, Andrew
    Castanares, Mark
    Stephens, Jennifer
    Ding, Yan
    Pratt, Susan
    Martinez, Ricardo
    Buchanan, Sean
    Reinhard, Christoph
    Beckmann, Richard
    Lin, Aimee
    CANCER RESEARCH, 2018, 78 (13)
  • [6] The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
    Tarantelli, Chiara
    Gaudio, Eugenio
    Hillmann, Petra
    Spriano, Filippo
    Sartori, Giulio
    Aresu, Luca
    Cascione, Luciano
    Rageot, Denise
    Kwee, Ivo
    Beaufils, Florent
    Zucca, Emanuele
    Stathis, Anastasios
    Wymann, Matthias P.
    Cmiljanovic, Vladimir
    Fabbro, Doriano
    Bertoni, Francesco
    CANCERS, 2019, 11 (06):
  • [7] Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models
    Caenepeel, Sean R.
    Belmontes, Brian
    Sun, Jan
    Coxon, Angela
    Moody, Gordon
    Hughes, Paul E.
    CANCER RESEARCH, 2017, 77
  • [8] CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents
    Perino, Samantha
    Kirby, R. Jason
    Agafonov, Roman
    Chaturvedi, Prasoon
    Eron, Scott
    Good, Andrew
    Hart, Ashley
    He, Minsheng
    Lobbardi, Riadh
    Phillips, Andrew J.
    Proia, David
    Henderson, James
    Thomeius, Michael
    Nasveschuk, Christopher
    Fisher, Stewart L.
    Pollock, Roy Macfarlane
    BLOOD, 2022, 140 : 11575 - 11575
  • [9] CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition
    Vo, Alex
    Taylor, Janelle
    Rosler, Robert
    Piasecki, Julia
    Leviten, Dina
    Sierra, Teresa
    Dozier, Ashley
    Klucher, Kevin
    Boyle, Bob
    Boyce, Rich
    Peterson, Scott
    CANCER RESEARCH, 2017, 77
  • [10] Anti-tumor activity and molecular correlates of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in models of human high-grade serous ovarian cancer (HGSOC)
    Wu, W.
    Dempsey, J.
    Abel, A.
    Donoho, G.
    Stephens, J.
    Iversen, P.
    Mc Nulty, A.
    Martinez, R.
    Mcneely, S.
    Szpurka, H.
    Schade, A.
    Reinhard, C.
    Stancato, L.
    Lin, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E4 - E4
12